Neutropenia in primary immunodeficiency

Current Opinion in Hematology

Volumn 20, Issue 1, 2013, Pages 55-65

  Sokolic, Robert ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Granulocyte colony stimulating factor; Hematopoietic cell transplantation; Neutropenia; Primary immunodeficiency disorders

Indexed keywords

ADENOSINE DEAMINASE; BUSULFAN; CHEMOKINE RECEPTOR CXCR4; GLUCOSE 6 PHOSPHATASE; GLUCOSE 6 PHOSPHATASE CATALYTIC UNIT 3; GRANULOCYTE ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; PEGYLATED ADENOSINE DEAMINASE; PLERIXAFOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE DEFICIENCY; BONE MARROW DISEASE; GLYCOGEN STORAGE DISEASE TYPE 1; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFECTION; LOW DRUG DOSE; MISSENSE MUTATION; MYELOKATHEXIS SYNDROME; NEUTROPENIA; NONHUMAN; POIKILODERMA; PRIORITY JOURNAL; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; VERRUCA VULGARIS;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; NEUTROPENIA;

EID: 84872002706     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32835aef1c     Document Type: Review

References (109)

1. Al-Herz W, Bousfiha A, Casanova J-L, et al. Primary immunodeficiency diseases: An update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. Front Immunol 2011; 2:1-26
2. Zeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009; 144:459-467
3. Carlsson G, Fasth A, Berglof E, et al. Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/ leukaemia. Br J Haematol 2012; 158:363-369
4. Ferry C, Ouachee M, Leblanc T, et al. Hematopoietic stem cell transplantation in severe congenital neutropenia: Experience of the French SCN register. Bone Marrow Transplant 2005; 35:45-50
5. Donini M, Fontana S, Savoldi G, et al. G-CSF treatment of severe congenital neutropenia reverses neutropenia but does not correct the underlying functional deficiency of the neutrophil in defending against microorganisms. Blood 2007; 109:4716-4723
6. Klein C, Grudzien M, Appaswamy G, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet 2007; 39:86-92
7. Boztug K, Appaswamy G, Ashikov A, et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med 2009; 360:32-43
8. Boztug K, Rosenberg PS, Dorda M, et al. Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: Novel genotypes and phenotypic variability in severe congenital neutropenia. J Pediatr 2012; 160:679-683; e672
9. McDermott DH, De Ravin SS, Jun HS, et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood 2010; 116:2793-2802
10. Person RE, Li FQ, Duan Z, et al. Mutations in proto-oncogene GFI1 cause human neutropenia and target ELA2. Nat Genet 2003; 34:308- 312
11. Khandanpour C, Thiede C, Valk PJ, et al. A variant allele of growth factor independence 1 (GFI1) is associated with acute myeloid leukemia. Blood 2010; 115:2462-2472
12. Huang M, Hu Z, Chang W. The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia. Acta Haematol 2010; 123:1-5
13. Donadieu J, Fenneteau O, Beaupain B, et al. Congenital neutropenia: Diagnosis, molecular bases and patient management. Orphanet J Rare Dis 2011; 6:26
14. Sinha S, Zhu QS, Romero G, Corey SJ. Deletional mutation of the external domain of the human granulocyte colony-stimulating factor receptor in a patient with severe chronic neutropenia refractory to granulocyte colonystimulating factor. J Pediatr Hematol/Oncol 2003; 25:791-796
15. Dale DC, Bolyard AA, Aprikyan A. Cyclic neutropenia. Semin Hematol 2002; 39:89-94
16. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol 2003; 72:82-93
17. Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006; 108:2182-2189
18. Beel K, Vandenberghe P. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica 2009; 94:1449-1452
19. Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27:313-317
20. Ochs HD. Mutations of the Wiskott-Aldrich syndrome protein affect protein expression and dictate the clinical phenotypes. Immunol Res 2009; 44:84- 88
21. Bouma G, Doffinger R, Patel SY, et al. Impaired neutrophil migration and phagocytosis in IRAK-4 deficiency. Br J Haematol 2009; 147:153-156
22. Singh A, Zarember KA, Kuhns DB, Gallin JI. Impaired priming and activation of the neutrophil NADPH oxidase in patients with IRAK4 or NEMO deficiency. J Immunol 2009; 182:6410-6417
23. Baldus M, Zunftmeister V, Geibel-Werle G, et al. Chediak-Higashi- Steinbrinck syndrome (CHS) in a 27-year-old woman: Effects of G-CSF treatment. Ann Hematol 1999; 78:321-327
24. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better? J Allergy Clin Immunol 2010; 126:602-610.e11
25. Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. Mol Gen Metab 1999; 68:283- 303
26. Wenham M, Grieve S, Cummins M, et al. Two patients with Hermansky Pudlak syndrome type 2 and novel mutations in AP3B1. Haematologica 2010; 95:333-337
27. Bohn G, Allroth A, Brandes G, et al. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. Nat Med 2007; 13:38-45
28. Bohn G, Hardtke-Wolenski M, Zeidler C, et al. Lethal graft-versus-host disease in congenital neutropenia caused by p14 deficiency after allogeneic bone marrow transplantation from an HLA-identical sibling. Pediatr Blood Cancer 2008; 51:436-438
29. Sokolic R, Maric I, Kesserwan C, et al. Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency. Blood 2011; 118:2688-2694
30. Ammann RA, Duppenthaler A, Bux J, Aebi C. Granulocyte colony-stimulating factor-responsive chronic neutropenia in cartilage-hair hypoplasia. J Pediatr Hematol/Oncol 2004; 26:379-381
31. Taskinen M, Ranki A, Pukkala E, et al. Extended follow-up of the Finnish cartilage-hair hypoplasia cohort confirms high incidence of non-Hodgkin lymphoma and basal cell carcinoma. Am J Med Genet A 2008; 146A:2370-2375
32. Guggenheim R, Somech R, Grunebaum E, et al. Bone marrow transplantation for cartilage-hair-hypoplasia. Bone Marrow Transplant 2006; 38:751- 756
33. Mäkitie O, Rajantie J, Kaitila I. Anaemia and macrocytosis: Unrecognized features in cartilage-hair hypoplasia. Acta Paediatr 1992; 81:1026- 1029
34. Azcona C, Alzina V, Barona P, et al. Use of recombinant human granulocytemacrophage colony stimulating factor in an infant with reticular dysgenesis. Eur J Pediatr 1994; 153:164-166
35. Abdollahpour H, Appaswamy G, Kotlarz D, et al. The phenotype of human STK4 deficiency. Blood 2012; 119:3450-3457
36. Nehme NT, Schmid JP, Debeurme F, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 2012; 119:3458-3468
37. Hannibal MC, Torgerson T. IPEX syndrome. GeneReviews. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. University of Washington, Seattle; 1993
38. Zhan H, Sinclair J, Adams S, et al. Immune reconstitution and recovery of FOXP3 (Forkhead Box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome. Pediatrics 2008; 121:e998-e1002
39. Baud O, Goulet O, Canioni D, et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 2001; 344:1758-1762
40. Roy-Ghanta S, Orange JS. Use of cytokine therapy in primary immunodeficiency. Clin Rev Allergy Immunol 2010; 38:39-53
41. Howard V, Myers LA, Williams DA, et al. Stem cell transplants for patients with X-linked agammaglobulinemia. Clin Immunol 2003; 107:98- 102
42. Notarangelo LD, Rawlings DJ, Sullivan KE. An exemplum of XLA. Clin Immunol 2008; 126:137-139
43. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper- IgM syndrome. J Pediatr 1997; 131:47-54
44. Rizzi M, Neumann C, Fielding AK, et al. Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. J Allergy Clin Immunol 2011; 128:1371-1374; e1372
45. Cham B, Bonilla MA, Winkelstein J. Neutropenia associated with primary immunodeficiency syndromes. Semin Hematol 2002; 39:107-112
46. Balabanian K, Lagane B, Pablos JL, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 2005; 105:2449-2457
47. Kriva'n G, Erdos M, Kállay K, et al. Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome. Eur J Haematol 2010; 84:274-275
48. Dale DC, Bolyard AA, Kelley ML, et al. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 2011; 118:4963-4966
49. McDermott DH, Liu Q, Ulrick J, et al. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome. Blood 2011; 118:4957-4962
50. Donadieu J, Bader-Meunier B, Bertrand Y, et al. Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. Report of 7 cases. Nouv Rev Fr He'matol 1994; 35:529- 534
51. Schroten H, Roesler J, Breidenbach T, et al. Granulocyte and granulocytemacrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib. J Pediatr 1991; 119:748-754
52. Pierre G, Chakupurakal G, McKiernan P, et al. Bone marrow transplantation in glycogen storage disease type 1b. J Pediatr 2008; 152:286-288
53. Rezaei N, Moazzami K, Aghamohammadi A, Klein C. Neutropenia and primary immunodeficiency diseases. Int Rev Immunol 2009; 28:335-366
54. Kivitie-Kallio S, Rajantie J, Juvonen E, Norio R. Granulocytopenia in Cohen syndrome. Br J Haematol 1997; 98:308-311
55. Seow WK, Bartold PM, Thong YH, Taylor K. Cohen syndrome with neutropenia- induced periodontitis managed with granulocyte colony-stimulating factor (G-CSF): Case reports. Pediatr Dent 1998; 20:350-354
56. Boerkoel CF, O'Neill S, Andre JL, et al. Manifestations and treatment of Schimke immuno-osseous dysplasia: 14 new cases and a review of the literature. Eur J Pediatr 2000; 159:1-7
57. Petty EM, Yanik GA, Hutchinson RJ, et al. Successful bone marrow transplantation in a patient with Schimke immuno-osseous dysplasia. J Pediatr 2000; 137:882-886
58. Thomas SE, Hutchinson RJ, DebRoy M, Magee JC. Successful renal transplantation following prior bone marrow transplantation in pediatric patients. Pediatr Transplant 2004; 8:507-512
59. Martin CC, Oeser JK, Svitek CA, et al. Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6- phosphatase catalytic subunit-related protein. J Mol Endocrinol 2002; 29:205-222
60. Guionie O, Clottes E, Stafford K, Burchell A. Identification and characterisation of a new human glucose-6-phosphatase isoform. FEBS Lett 2003; 551:159-164
61. Banka S, Chervinsky E, Newman WG, et al. Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3. Eur J Hum Genet 2011; 19:18-22
62. Gatti S, Boztug K, Pedini A, et al. A case of syndromic neutropenia and mutation in G6PC3. J Pediatr Hematol/Oncol 2011; 33:138-140
63. Cheung YY, Kim SY, Yiu WH, et al. Impaired neutrophil activity and increased susceptibility to bacterial infection in mice lacking glucose-6-phosphatasebeta. J Clin Invest 2007; 117:784-793
64. Jun HS, Lee YM, Cheung YY, et al. Lack of glucose recycling between endoplasmic reticulum and cytoplasm underlies cellular dysfunction in glucose- 6-phosphatase-beta-deficient neutrophils in a congenital neutropenia syndrome. Blood 2010; 116:2783-2792
65. Jun HS, Lee YM, Song KD, et al. G-CSF improves murine G6PC3-deficient neutrophil function by modulating apoptosis and energy homeostasis. Blood 2011; 117:3881-3892
66. Hayee B, Antonopoulos A, Murphy EJ, et al. G6PC3 mutations are associated with a major defect of glycosylation: A novel mechanism for neutrophil dysfunction. Glycobiology 2011; 21:914-924
67. Volpi L, Roversi G, Colombo EA, et al. Targeted next-generation sequencing appoints c16orf57 as Clericuzio-type poikiloderma with neutropenia gene. Am J Hum Genet 2010; 86:72-76
68. Colombo EA, Bazan JF, Negri G, et al. Novel C16orf57 mutations in patients with poikiloderma with neutropenia: Bioinformatic analysis of the protein and predicted effects of all reported mutations. Orphanet J Rare Dis 2012; 7:7
69. Walne AJ, Vulliamy T, Beswick R, et al. Mutations in C16orf57 and normallength telomeres unify a subset of patients with dyskeratosis congenita, poikiloderma with neutropenia and Rothmund-Thomson syndrome. Hum Mol Genet 2010; 19:4453-4461
70. Wetzler M, Talpaz M, Kleinerman ES, et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. Am J Med 1990; 89:663-672
71. Hernandez PA, Gorlin RJ, Lukens JN, et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 2003; 34:70-74
72. McDermott DH, Lopez J, Deng F, et al. AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome. J Cell Mol Med 2011; 15:2071-2081
73. Kawai T, Malech HL. WHIM syndrome: Congenital immune deficiency disease. Curr Opin Hematol 2009; 16:20-26
74. Liu Q, Chen H, Ojode T, et al. WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood 2012; 120:181-189
75. Doncker AV, Balabanian K, Bellanné-Chantelot C, et al. Two cases of disseminated Mycobacterium avium infection associated with a new immunodeficiency syndrome related to CXCR4 dysfunctions. Clin Microbiol Infect 2011; 17:135-139
76. Balabanian K, Levoye A, Klemm L, et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest 2008; 118:1074-1084
77. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360:447- 458
78. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009; 15:1628-1633
79. Engel BC, Podsakoff GM, Ireland JL, et al. Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: A case report. Blood 2007; 109:503-506
80. Sokolic R, Muul L, Garabedian E, et al. Systemic effects of PEG-ADA withdrawal with or without chemotherapy (Chtx) and cytotherapy (CTx) in adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID). J Clin Immunol 2012; 32:404
81. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56-e93
82. Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284:1061-1065
83. Fioredda F, Calvillo M, Bonanomi S, et al. Congenital and acquired neutropenia consensus guidelines on diagnosis from the Neutropenia Committee of the Marrow Failure Syndrome Group of the AIEOP (Associazione Italiana Emato- Oncologia Pediatrica). Pediatr lood Cancer 2011; 57:10-17
84. Dale DC, Bonilla MA, Davis MW, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993; 81:2496-2502
85. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 2006; 107:4628-4635
86. Zeidler C, Welte K. Hematopoietic growth factors for the treatment of inherited cytopenias. Semin Hematol 2007; 44:133-137
87. Zeidler C, Boxer L, Dale DC, et al. Management of Kostmann syndrome in the G-CSF era. Br J Haematol 2000; 109:490-495
88. Ward AC, van Aesch YM, Gits J, et al. Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment. J Exp Med 1999; 190:497-508
89. Druhan LJ, Ai J, Massullo P, et al. Novel mechanism of G-CSF refractoriness in patients with severe congenital neutropenia. Blood 2005; 105:584-591
90. Choi LM, Guelcher C, Guerrera MF. Novel treatment for severe congenital neutropenia with pegfilgrastim. Blood 2007; 110:4134
91. Draper BK, Robbins JB, Stricklin GP. Bullous Sweet's syndrome in congenital neutropenia: Association with pegfilgrastim. J Am Acad Dermatol 2005; 52:901-905
92. Fioredda F, Calvillo M, Lanciotti M, et al. Pegfilgrastim in children with severe congenital neutropenia. Pediatr Blood Cancer 2010; 54:465-467
93. Lahteenmäki PM, Jahnukainen K, Pelliniemi T-T, et al. Severe congenital neutropenia and pegfilgrastim. Eur J Haematol 2009; 82:75-76
94. Donadieu J, Beaupain B, Rety-Jacob F, Nove-Josserand R. Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: Possible role of pegfilgrastim. Haematologica 2009; 94:1175-1177
95. Beaupain B, Leblanc T, Reman O, et al. Is pegfilgrastim safe and effective in congenital neutropeniäAn analysis of the French Severe Chronic Neutropenia registry. Pediatr Blood Cancer 2009; 53:1068-1073
96. Buckley R, Fischer A. Bone marrow transplantation for primary immunodeficiency diseases. In: Ochs H, Smith C, Puck J, editors. Primary immunodeficiency diseases: A molecular and genetic approach, 2nd ed. Oxford University Press; 2007. pp. 669-687
97. Small T, Friedrich W, O'Reilly R. Hematopoietic cell transplantation for immunodeficiency diseases. In: Appelbaum F, Forman S, Negrin R, Bliume K, editors. Thomas' hematopoietic cell transplantation, 4th ed. Wiley-Blackwell; 2009. pp. 1105-1124
98. Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: Longterm outcomes. Immunol Res 2011; 49:25-43
99. Gaspar HB, Aiuti A, Porta F, et al. How I treat ADA deficiency. Blood 2009; 114:3524-3532
100. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296:2410-2413
101. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-1193
102. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12:401-409
103. Boztug K, Dewey RA, Diez IA, et al. Hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Blood 2007; 110:502
104. Sokolic R, Podsakoff G, Muul L, et al. Comparative results of gene therapy for adenosine deaminase deficiency with or without PEG-ADA withdrawal and myelosuppressive chemotherapy. Blood 2007; 110:154a.
105. Kang EM, Choi U, Theobald N, et al. Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils. Blood 2010; 115:783-791
106. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminasedeficient severe combined immune deficiency: Clinical comparison of retroviral vectors and treatment plans. Blood 2012; 120:3635-3646
107. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-256
108. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-419
109. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16:198-204